¹⁷⁷Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):166-167. doi: 10.1007/s00259-016-3530-2. Epub 2016 Oct 4.

Authors

Kambiz Rahbar¹, Martin Bögemann², Hojjat Ahmadzadehfar³

Affiliations

¹ Department of Nuclear Medicine, University Hospital of Muenster, Muenster, Germany. [email protected].
² Department of Urology, University Hospital of Muenster, Muenster, Germany.
³ Department of Nuclear Medicine, University Hospital of Bonn, Bonn, Germany.

PMID: 27699719
DOI: 10.1007/s00259-016-3530-2

No abstract available

Keywords: PSMA-617; Radioligand therapy; mCRPC.

Publication types

Letter

MeSH terms

Bone Neoplasms / radiotherapy*
Bone Neoplasms / secondary*
Dipeptides / therapeutic use*
Heterocyclic Compounds, 1-Ring / therapeutic use*
Humans
Lutetium
Male
Outcome Assessment, Health Care / methods*
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant / radiotherapy*
Radiopharmaceuticals / therapeutic use
Radiotherapy / methods*
Treatment Outcome

Substances

Pluvicto
Dipeptides
Heterocyclic Compounds, 1-Ring
Radiopharmaceuticals
Lutetium
Prostate-Specific Antigen